One email when the decision is public, with what it means in plain language. You'll also get new trials and FDA news for Achondroplasia. Unsubscribe anytime.
- Trial Alerts, when a new trial opens or a trial changes
- Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
The FDA is expected to decide on Voxzogo for Achondroplasia (conversion to full approval) by February 28, 2027, under a sNDA from BioMarin.
What the FDA is deciding on Voxzogo for Achondroplasia
The FDA is reviewing BioMarin's request to update the label of Voxzogo (vosoritide) for achondroplasia (conversion to full approval). Application to convert the 2021 accelerated approval into full approval.
Who the Voxzogo decision matters to
Achondroplasia is the most common form of short-limbed dwarfism, caused by a mutation in the FGFR3 gene that disrupts the conversion of cartilage to bone in the growth plates. This results in disproportionate short stature with an average-size trunk but shortened arms and legs.
About 80% of cases arise from new spontaneous mutations rather than being inherited from an affected parent.
Prevalence: Approximately 1 in 25,000 live births; estimated 25,000 to 30,000 people in the United States. See our full Achondroplasia page for current treatments, recruiting trials, and community resources.
How Voxzogo works
Voxzogo: c-type natriuretic peptide (CNP) analog that binds the NPR-B receptor and dampens the signaling switched on by the overactive FGFR3 receptor, which lets the growth plates make bone faster. Our full Voxzogo profile covers how it works, side effects in plain language, and its trial history.
What an approval or a rejection of Voxzogo would mean
Voxzogo is already sold in the US for Achondroplasia, so an approval changes its label rather than whether families can get it.
A complete response letter would mean the FDA declined to approve in the application's current form. The letter describes what the FDA wants addressed, and the company then decides whether to resubmit, run more studies or stop. Either way, this page updates with the outcome and what it means.
Where Achondroplasia treatment stands today
Read our full Achondroplasia treatment summary
Clinical trials for achondroplasia are exploring multiple strategies to promote bone growth and address the complications of FGFR3 overactivation. Voxzogo (vosoritide), a daily injection approved in November 2021, established the path for growth-promoting therapies, and in February 2026 the FDA approved Yuviwel (navepegritide), a once-weekly CNP injection for children 2 and older whose growth plates are still open.
Both received accelerated approval based on faster yearly growth, and continued approval of each depends on confirmatory trials. BridgeBio announced on October 6, 2026 that the FDA had accepted its application for infigratinib, a once-daily pill that blocks FGFR3, for children with achondroplasia, with a decision due February 4, 2027.
Other studies are recruiting, according to ClinicalTrials.gov in October 2026. BioMarin's ASPEN study compares its longer-acting CNP drug BMN 333 with Voxzogo in children 2 to 17 (NCT07441876).
Tyra Biosciences is testing TYRA-300, a drug that blocks FGFR3, in children 3 to 10 (NCT06842355), and BridgeBio and Ascendis are testing infigratinib and Yuviwel in babies and toddlers under 3 (NCT07169279, NCT06079398).
Trials measure treatment response through growth velocity, body proportions, and functional outcomes like mobility and respiratory function. For children, early enrollment in growth-promoting trials may maximize benefit while growth plates remain open.
Adults with achondroplasia may benefit from trials addressing spinal stenosis, sleep apnea, and pain management.
Your geneticist, orthopedic specialist, or skeletal dysplasia clinic can help evaluate whether current trials are appropriate. Little People of America and the MAGIC Foundation maintain information on clinical trials and connect families with specialized care centers.
The Achondroplasia page has every treatment and trial →Meanwhile, 10 Achondroplasia studies are open or about to open
Whatever the FDA decides here, research on Achondroplasia does not stop. Of these, 5 test a treatment; the others follow patients over time. The most recently updated:
We'll email you when the decision is public, with what it means in plain language, and when new trials open for Achondroplasia. Unsubscribe anytime.
- Trial Alerts, when a new trial opens or a trial changes
- Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
Frequently asked questions
When will the FDA decide on Voxzogo?
The FDA's target date (PDUFA date) for Voxzogo in Achondroplasia (conversion to full approval) is February 28, 2027.
Who disclosed it: BioMarin. The FDA does not publish these dates.
Can it move: the FDA can act early, and a major amendment to the application can push the date back 3 months.
Source: BioMarin press release
What is Voxzogo being reviewed for?
BioMarin submitted a sNDA for Voxzogo in Achondroplasia (conversion to full approval).
What to know: Application to convert the 2021 accelerated approval into full approval.
How it works: C-type natriuretic peptide (CNP) analog that binds the NPR-B receptor and dampens the signaling switched on by the overactive FGFR3 receptor, which lets the growth plates make bone faster.
More: the Voxzogo drug page explains it in plain language.
Is there already an FDA-approved treatment for Achondroplasia?
Yes. Trial Friend's drug list includes 2 FDA-approved drugs for Achondroplasia.
Approved: Voxzogo (vosoritide), Yuviwel (navepegritide).
Check: the Achondroplasia page also searches FDA drug labels for approved treatments.
What did the Voxzogo trials show?
Accelerated approval rested on Study 1 (NCT03197766), which randomly assigned 121 children aged 5.1-14.9 with achondroplasia to daily Voxzogo (60 children) or placebo (61) for 52 weeks. Children on Voxzogo grew 1.57cm a year more than children on placebo (95% CI 1.22 to 1.93), and their height compared with other children with achondroplasia also improved.
More: the Voxzogo drug page has the full trial history and sources.
What are the side effects of Voxzogo?
Voxzogo has no boxed warning and no contraindications. Its one warning is about low blood pressure.
Most common: Injection site redness (75% against 69% on placebo), Injection site swelling (62% against 36%), Vomiting (27% against 20%), Injection site hives (25% against 10%), Joint pain (15% against 7%), Lower blood pressure (13% against 5%).
More: the Voxzogo drug page has the label's warnings in full.
Can I get Voxzogo before the FDA decides?
Voxzogo is already FDA approved for Achondroplasia. This decision is about a change to its label. Ask your doctor whether the current label already covers you.
Trials: 10 Achondroplasia studies are open or about to open, 5 of them testing a treatment. See them.
Check your fit: Match Me compares your details with every open trial.
Expanded access: your doctor can ask BioMarin directly. Registered programs are listed on ClinicalTrials.gov.
How much will Voxzogo cost?
Voxzogo is already sold in the US for Achondroplasia. Trial Friend does not list a price, and what you pay depends on your insurer and drugmaker help.
Drugmaker help: BioMarin RareConnections.
Find help: the patient assistance finder lists programs by insurance type.
What happens after the Voxzogo decision?
This page updates with the outcome the day it is announced.
If approved: the label changes. Voxzogo is already sold in the US for this condition, so there is no new launch to wait for.
If not approved: a complete response letter means the FDA declined the application in its current form. Many are about manufacturing or how data were presented, and companies often resubmit.
Where this date comes from
The FDA does not publish PDUFA dates; companies disclose them. This one comes from BioMarin press release. Dates can move, and the FDA can act early or late. This page rechecks against our calendar, which is re-verified daily.